On
September 19, 2012, a French Navy (Marine Nationale) Rafale M was launched from
the nuclear powered aircraft carrier Charles de Gaulle (R91) and fired an
Exocet anti-ship missile according to the French aerospace magazine Air &
Cosmos.
The AM39
Block2 Mod2 Exocet missile, which was live round, destroyed its target at sea.
The test, which was a first for the French Navy (previous tests were conducted
either by Dassault or by an evaluation unit), validates the anti-ship missile
for future operational use.
On
September 19, 2012, a French Navy (Marine Nationale) Rafale M was launched from
the nuclear powered aircraft carrier Charles de Gaulles (R91) and fired an
Exocet anti-ship missile according to the French aerospace magazine Air &
Cosmos. A Rafale M with an AM39 Exocet is launched from the aircraft carrier
Charles de Gaulle
(Archive
picture: French Navy)
The
Exocet AM39 Anti-ship missile is in service with the French armed forces and
the navies of 11 other countries. In January 2004, the French DGA (Direction
Générale de l’Armement) awarded MBDA with the contract covering the development
of both the Exocet AM39 Block2 Mod2 and the Exocet MM40 Block3.
In June
2007, the latest Mod2 development of the Exocet AM39 Block2 completed its final
validation firing from a naval Rafale F3 combat aircraft. The firing also
served as the validation firing for the Rafale in its F3 standard. The Mod2
evolution has seen the digitisation of Exocet AM39 Block2, an adaptation called
for by the requirements of the latest generation of rotary and fixed wing
aircraft such as the Rafale F3.
The
Exocet has an OTH (Over The Horizon) firing capacity and a range of other
operational benefits including :
• low
signature
• late
seeker activation
•
sea-skimming at very low altitude
•
enhanced target discrimination and ECCM
• high
penetrative power against modern naval air defences.
The
Exocet AM39 can be launched from a range of platforms: fighter aircraft,
maritime patrol aircraft and medium or heavy helicopters at stand-off ranges.
No comments:
Post a Comment